Literature DB >> 30266818

Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study.

Ada Gillissen1,2,3, Thomas van den Akker3,4, Camila Caram-Deelder1,2, Dacia D C A Henriquez1,2,3, Kitty W M Bloemenkamp5, Moniek P M de Maat6, Jos J M van Roosmalen3,7, Joost J Zwart8, Jeroen Eikenboom9, Johanna G van der Bom1,2.   

Abstract

We describe the pattern of change in coagulation parameters during the course of severe postpartum hemorrhage in a retrospective cohort study among 1312 women experiencing severe postpartum hemorrhage necessitating blood transfusion. Levels of hemoglobin, hematocrit, platelet count, fibrinogen, activated partial thromboplastin time (aPTT) and prothrombin time (PT) per categorized volume of blood loss during severe postpartum hemorrhage were described and compared between women with and without the composite adverse outcome. Need for surgical intervention, severe acute maternal morbidity, and maternal mortality were jointly considered the composite adverse outcome. Of the 1312 women, 463 (35%) developed the composite adverse outcome. The incidence of a fibrinogen level <2 g/L was 26% (342 per 1312). Low fibrinogen and prolonged aPTT during the first 2 L of hemorrhage were associated with a subsequent composite adverse outcome; median fibrinogen and aPTT among women with and without the composite end point after 1.5 to 2 L of hemorrhage were 1.5 g/L (interquartile range [IQR], 1.0-1.9) vs 2.7 g/L (IQR, 1.9-3.4) and 39 s (IQR, 30-47) vs 32 s (IQR, 28-36), respectively. PT and platelet count as assessed during the first 2 L of hemorrhage were not associated with morbidity or mortality. Our results suggest that detection of low levels of fibrinogen and elevated aPTT levels during early postpartum hemorrhage can contribute to the identification of women that may benefit from targeted hemostatic treatment. Essential in this identification process is the moment of reaching a level of fibrinogen of <2 g/L during the course of postpartum hemorrhage.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30266818      PMCID: PMC6177656          DOI: 10.1182/bloodadvances.2018022632

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  23 in total

1.  Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study.

Authors:  J E Lutomski; B M Byrne; D Devane; R A Greene
Journal:  BJOG       Date:  2011-12-13       Impact factor: 6.531

2.  Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.

Authors:  Marcel Adler; Sandra Ivic; Nicolas S Bodmer; Hugo Ten Cate; Lucas M Bachmann; Walter A Wuillemin; Michael Nagler
Journal:  Transfus Med Hemother       Date:  2017-03-08       Impact factor: 3.747

3.  Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial.

Authors:  A J Wikkelsø; H M Edwards; A Afshari; J Stensballe; J Langhoff-Roos; C Albrechtsen; K Ekelund; G Hanke; E L Secher; H F Sharif; L M Pedersen; A Troelstrup; J Lauenborg; A U Mitchell; L Fuhrmann; J Svare; M G Madsen; B Bødker; A M Møller
Journal:  Br J Anaesth       Date:  2015-01-13       Impact factor: 9.166

4.  Increasing incidence of postpartum hemorrhage: the Dutch piece of the puzzle.

Authors:  Giel van Stralen; Joost F von Schmidt Auf Altenstadt; Kitty W M Bloemenkamp; Jos van Roosmalen; Chantal W P M Hukkelhoven
Journal:  Acta Obstet Gynecol Scand       Date:  2016-08-23       Impact factor: 3.636

5.  Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial.

Authors:  M Cortet; C Deneux-Tharaux; C Dupont; C Colin; R-C Rudigoz; M-H Bouvier-Colle; C Huissoud
Journal:  Br J Anaesth       Date:  2012-04-06       Impact factor: 9.166

6.  Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both?

Authors:  O Karlsson; A Jeppsson; M Hellgren
Journal:  Int J Obstet Anesth       Date:  2013-12-15       Impact factor: 2.603

7.  Investigation of an increase in postpartum haemorrhage in Canada.

Authors:  K S Joseph; J Rouleau; M S Kramer; D C Young; R M Liston; T F Baskett
Journal:  BJOG       Date:  2007-06       Impact factor: 6.531

Review 8.  Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group.

Authors:  Marian Knight; William M Callaghan; Cynthia Berg; Sophie Alexander; Marie-Helene Bouvier-Colle; Jane B Ford; K S Joseph; Gwyneth Lewis; Robert M Liston; Christine L Roberts; Jeremy Oats; James Walker
Journal:  BMC Pregnancy Childbirth       Date:  2009-11-27       Impact factor: 3.007

9.  Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial.

Authors:  P W Collins; R Cannings-John; D Bruynseels; S Mallaiah; J Dick; C Elton; A D Weeks; J Sanders; N Aawar; J Townson; K Hood; J E Hall; R E Collis
Journal:  Br J Anaesth       Date:  2017-09-01       Impact factor: 9.166

10.  The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study.

Authors:  Ada Gillissen; Dacia D C A Henriquez; Thomas van den Akker; Camila Caram-Deelder; Merlijn Wind; Joost J Zwart; Jos van Roosmalen; Jeroen Eikenboom; Kitty W M Bloemenkamp; Johanna G van der Bom
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

View more
  6 in total

1.  A regional massive hemorrhage protocol developed through a modified Delphi technique.

Authors:  Jeannie L Callum; Calvin H Yeh; Andrew Petrosoniak; Mark J McVey; Stephanie Cope; Troy Thompson; Victoria Chin; Keyvan Karkouti; Avery B Nathens; Kimmo Murto; Suzanne Beno; Jacob Pendergrast; Andrew McDonald; Russell MacDonald; Neill K J Adhikari; Asim Alam; Donald Arnold; Lee Barratt; Andrew Beckett; Sue Brenneman; Hina Razzaq Chaudhry; Allison Collins; Margaret Harvey; Jacinthe Lampron; Clarita Margarido; Amanda McFarlan; Barto Nascimento; Wendy Owens; Menaka Pai; Sandro Rizoli; Theodora Ruijs; Robert Skeate; Teresa Skelton; Michelle Sholzberg; Kelly Syer; Jami-Lynn Viveiros; Josee Theriault; Alan Tinmouth; Rardi Van Heest; Susan White; Michelle Zeller; Katerina Pavenski
Journal:  CMAJ Open       Date:  2019-09-03

2.  Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement.

Authors:  Manuel Muñoz; Jakob Stensballe; Anne-Sophie Ducloy-Bouthors; Marie-Pierre Bonnet; Edoardo De Robertis; Ino Fornet; François Goffinet; Stefan Hofer; Wolfgang Holzgreve; Susana Manrique; Jacky Nizard; François Christory; Charles-Marc Samama; Jean-François Hardy
Journal:  Blood Transfus       Date:  2019-02-06       Impact factor: 3.443

3.  Efficacy of sonorheometry point of the care device in determining low fibrinogen levels in pregnant blood: an invitro dilution and reconstitution study.

Authors:  Bhavani Shankar Kodali; Arun Karuppiah; Shobana Bharadwaj; Jonathan Chow; Kenichi Tanaka
Journal:  J Clin Monit Comput       Date:  2021-12-03       Impact factor: 1.977

4.  Digital postpartum hemorrhage management device (DPHMD).

Authors:  Derartu D Tekela; Abeba G Asmare; Birhan M Gebremariam; Christian A Assegahegn; Kidist D Wami; Hundessa D Nemomssa; Gizeaddis L Simegn
Journal:  BMC Pregnancy Childbirth       Date:  2019-11-26       Impact factor: 3.007

5.  Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage.

Authors:  Dacia D C A Henriquez; Camila Caram-Deelder; Saskia le Cessie; Joost J Zwart; Jos J M van Roosmalen; Jeroen C J Eikenboom; Cynthia So-Osman; Leo M G van de Watering; Jaap Jan Zwaginga; Ankie W M M Koopman-van Gemert; Kitty W M Bloemenkamp; Johanna G van der Bom
Journal:  JAMA Netw Open       Date:  2019-11-01

6.  Perioperative Cryoprecipitate Waste Reduction.

Authors:  Camden Burk; Kent Eliason; Allison Doney; Jeremi Mountjoy; Adam A Dalia
Journal:  J Med Syst       Date:  2021-02-10       Impact factor: 4.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.